BURLINGTON, Ontario–(BUSINESS WIRE)–Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE), a Canadian biotechnology company revolutionizing drug delivery through innovation, has completed a significant shipment of one million QuickStrip™ units to one of Canada’s largest cannabis companies.
Three unique formulations – 10mg THC, 20mg CBD and 20mg 1:1 ratio THC & CBD – were developed by RDT for use by medical cannabis patients following strictly controlled standard operating procedures and post-production testing requirements.
The adoption of the QuickStrip™ as a viable drug delivery method has confirmed and validated the technology as an effective needle free COVID-19 vaccine candidate.
“This significant order provided the opportunity for our RDT team to further streamline and perfect our manufacturing process, which will become increasingly relevant as we scale up for larger cannabis and nutraceutical production needs,” said Mark Upsdell, CEO, Rapid Dose Therapeutics. “This manufacturing and operational excellence is also ideally suited to support the research expansion of our oral vaccine candidate for COVID-19 as we get closer to starting human trials where production volume will be key.”
About Rapid Dose Therapeutics Corp.
Rapid Dose Therapeutics is a Canadian biotechnology company revolutionizing drug delivery through innovation. The Company’s flagship product QuickStrip™ is a thin, orally dissolvable film, that can be infused with an infinite list of active ingredients (nutraceuticals, pharmaceuticals, vaccines, cannabis) that are delivered quickly into the bloodstream resulting in rapid onset of the active ingredient.
www.rapid-dose.com
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS:
Certain information in this news release may contain forward-looking information within the meaning of applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as “may”, “should”, “anticipate”, “expect”, “potential”, “believe”, “intend”, “will”, “could”, “are planned to”, “are expected to” or the negative of these terms and similar expressions. Statements containing forward-looking information, including, without limitation, in respect of the delivery of equipment and products using the QuickStrip™ product delivery method, the generation of recurring revenues, as at the date of this news release, the plans, estimates, forecasts, projections, expectations or beliefs of RDT management as to future events or results and are believed to be reasonable based on information currently available to RDT management. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; termination of WLM agreements; future legislative and regulatory developments involving cannabis; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the cannabis industry in Canada generally, income tax and regulatory matters; the ability to implement its business strategies; competition; currency and interest rate fluctuations and other risks. Readers are cautioned that the foregoing list is not exhaustive. There can be no assurance that statements of forward-looking information, although considered reasonable by RDT management at the time of preparation, will prove to be accurate as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. Actual results and future events could differ materially from those anticipated in such forward-looking statements. Readers should not place undue reliance on forward-looking statements. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.
Contacts
Investor Contact:
Mark Upsdell, CEO
mupsdell@rapid-dose.com
416-477-1052
Media Contact:
Kim Robinson
krobinson@rapid-dose.com
905-330-4055